News | October 26, 2009

First Intra-Arrest Cooling Study to be Presented at AHA

October 23, 2009 – The first randomized intra-arrest cooling study has been selected for presentation as a late-breaking trial during the American Heart Association's (AHA) Scientific Sessions in November.

The Pre-Resuscitation Intra-Nasal Cooling Effectiveness (PRINCE) study was conducted by 15 emergency medical systems (EMS) in Belgium, Germany, Italy, Czech Republic and Sweden with 200 patients to determine whether the addition of direct-to-the-brain cooling during cardiac arrest has a beneficial effect. The study was conducted using a novel, non-invasive nasal catheter, which sprays evaporative coolant liquid into the nasal cavity, right beneath the brain.

Therapeutic hypothermia currently is recommended for patients successfully resuscitated from cardiac arrest once they reach the hospital. However, many medical professionals believe that cooling could be more effective if started earlier, ideally at the time of arrest, but current hypothermia methods are not practical in this setting. The PRINCE study tested rapid initiation of brain cooling at the site of arrest even before normal circulation was reestablished.

Lead investigator and study coauthor Maaret Castren, M.D., Ph.D. of the department of clinical science and education, Karolinska Institute, Stockholm, Sweden and the department of emergency medicine, Sodersjukhuset will present the findings at 6:15 p.m. EST, Sunday, Nov. 15 in Orlando, Fla., during the AHA's Resuscitation Science Symposium "Best of the Best" presentations.

The study was sponsored by BeneChill. The company’s RhinoChill was used in the PRINCE study and can be administered quickly and directly to the brain by a proprietary portable system that uses a nasal catheter to deliver a rapid evaporative coolant. RhinoChill will be marketed in Europe in early 2010 and currently is an investigational device in the United States.

For more information: www.benechill.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now